Ebolavirus vaccines for humans and apes

Hugues Fausther-Bovendo; Sabue Mulangu; Nancy J. Sullivan

doi:10.1016/j.coviro.2012.04.003

Ebolavirus vaccines for humans and apes

Hugues Fausther-Bovendo
, Sabue Mulangu
, Nancy J. Sullivan

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made. Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes.

Original language	English (US)
Pages (from-to)	324-329
Number of pages	6
Journal	Current Opinion in Virology
Volume	2
Issue number	3
DOIs	https://doi.org/10.1016/j.coviro.2012.04.003
State	Published - Jun 2012
Externally published	Yes

ASJC Scopus subject areas

Virology

Access to Document

10.1016/j.coviro.2012.04.003

Cite this

@article{69d6a93ccff941d4ae5515cb7257f587,

title = "Ebolavirus vaccines for humans and apes",

abstract = "Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made. Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes.",

author = "Hugues Fausther-Bovendo and Sabue Mulangu and Sullivan, \{Nancy J.\}",

year = "2012",

month = jun,

doi = "10.1016/j.coviro.2012.04.003",

language = "English (US)",

volume = "2",

pages = "324--329",

journal = "Current Opinion in Virology",

issn = "1879-6257",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Ebolavirus vaccines for humans and apes

AU - Fausther-Bovendo, Hugues

AU - Mulangu, Sabue

AU - Sullivan, Nancy J.

PY - 2012/6

Y1 - 2012/6

N2 - Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made. Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes.

AB - Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made. Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes.

UR - https://www.scopus.com/pages/publications/84862861509

UR - https://www.scopus.com/pages/publications/84862861509#tab=citedBy

U2 - 10.1016/j.coviro.2012.04.003

DO - 10.1016/j.coviro.2012.04.003

M3 - Review article

C2 - 22560007

AN - SCOPUS:84862861509

SN - 1879-6257

VL - 2

SP - 324

EP - 329

JO - Current Opinion in Virology

JF - Current Opinion in Virology

IS - 3

ER -

Ebolavirus vaccines for humans and apes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this